HEALTH Bharat Biotech submits Covaxin trial data for ages 2-18 to DCGI: Report Covid-19 vaccine Covaxin manufacturer Bharat Biotech has submitted the trial data for children in the 2-18 years age group to the DCGI.
HEALTH Mansukh Mandaviya launches 1st commercial batch of Bharat Biotech's COVAXIN manufactured in Ankleshwar Union Minister of Health and Family Welfare Mansukh Mandaviya on August 29 released the first commercial batch of Bharat Biotech's COVAXIN manufactured at Ankleshwar in Gujarat
HEALTH DCGI gives nod for conducting study on mixing vaccines The Drugs Controller General of India (DCGI) approved a study on mixing Covaxin and Covishield Covid-19 vaccines in India on Tuesday.
HEALTH Mixing of Covid vaccines is 'wrong’, says Serum’s Cyrus Poonawalla Cyrus Poonawalla, chairman of the Serum Institute of India, says mixing of COVID-19 vaccines both Covishield and Covaxin is "wrong".
HEALTH Bharat Biotech concludes final analysis for Covaxin Hyderabad-based Bharat Biotech concluded a final analysis for its vaccine Covaxin efficacy from a phase-3 clinical trial, which claimed it to be 77.8 percent effective against COVID-19. It also states that Covaxin gives 65.2 percent protection against SARS-CoV-2, B.1.617.2 delta variant.
/dnp-english/media/agency_attachments/2024/11/25/2024-11-25t064936166z-dnp-india-logo-640x480-dnp-news-2.png){kind=logo}